
Microbot Medical (MBOT) Stock Forecast & Price Target
Microbot Medical (MBOT) Analyst Ratings
Bulls say
Microbot Medical Inc. has improved its financial position through recent equity financings and option exercises, resulting in a significant increase in financing income, rising to $284,000 for the quarter and $611,000 year-to-date from $144,000 last year. The company is preparing for its full market launch of the LIBERTY Endovascular Robotic System, enhancing its commercial and production capabilities by expanding its team and securing a partnership with a third-party logistics provider, which supports operational readiness. Additionally, the positive feedback from healthcare providers regarding the product underscores its market potential, suggesting a strong foundation for anticipated growth as the company plans to enter major markets in the coming years.
Bears say
Microbot Medical Inc faces significant risks that adversely impact its financial outlook, including delays in the commercialization of its LIBERTY Endovascular Robotic System and challenges in expanding into the cardiac and neurological markets. The company also grapples with reimbursement headwinds, lack of near-term profitability, and potential erosion of hospital margins due to the device's costs, which could hinder its adoption. Additionally, the absence of data from randomized controlled trials and setbacks in securing international regulatory approvals contribute to a challenging market environment, posing threats to the company's financial performance and growth trajectory.
This aggregate rating is based on analysts' research of Microbot Medical and is not a guaranteed prediction by Public.com or investment advice.
Microbot Medical (MBOT) Analyst Forecast & Price Prediction
Start investing in Microbot Medical (MBOT)
Order type
Buy in
Order amount
Est. shares
0 shares